STERIS plc $STE Shares Sold by Boston Trust Walden Corp

Posted by on Jul 3rd, 2026

Boston Trust Walden Corp lessened its stake in STERIS plc (NYSE:STE – Free Report) by 3.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 307,828 shares of the medical equipment provider’s stock after selling 10,445 shares during the quarter. Boston Trust Walden Corp’s holdings in STERIS were worth $68,070,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in STE. Board of the Pension Protection Fund purchased a new position in STERIS during the fourth quarter valued at $25,000. Activest Wealth Management grew its position in shares of STERIS by 423.8% in the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 89 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in shares of STERIS during the fourth quarter worth about $28,000. Harbor Investment Advisory LLC increased its stake in shares of STERIS by 115.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 60 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its position in shares of STERIS by 342.3% during the 4th quarter. Cornerstone Planning Group LLC now owns 115 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

STERIS Price Performance

STERIS stock opened at $217.94 on Friday. The company has a fifty day simple moving average of $212.02 and a 200-day simple moving average of $231.92. The firm has a market capitalization of $21.24 billion, a price-to-earnings ratio of 27.48 and a beta of 0.92. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44.

STERIS (NYSE:STE – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the previous year, the firm posted $2.74 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, equities analysts anticipate that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Monday, June 8th were given a dividend of $0.63 per share. The ex-dividend date was Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on STE shares. KeyCorp decreased their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings lowered STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Wall Street Zen cut STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $270.00 target price on shares of STERIS in a research report on Thursday, May 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

View Our Latest Analysis on STE

Insider Buying and Selling

In other STERIS news, Director Richard C. Breeden sold 1,481 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the sale, the director directly owned 38,964 shares in the company, valued at $8,163,347.64. This represents a 3.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel A. Carestio sold 3,054 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $214.64, for a total value of $655,510.56. Following the completion of the sale, the chief executive officer directly owned 65,021 shares of the company’s stock, valued at $13,956,107.44. This trade represents a 4.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 7,328 shares of company stock worth $1,554,051. 1.12% of the stock is owned by corporate insiders.

STERIS Profile

(Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.

Featured Stories

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.